Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning everyone and welcome to the Abiona Therapeutics full year 2025 results conference call. At this time all participants are in a listen only mode and the floor will be open for questions following the presentation. If anyone should require operator assistance during this conference please press star zero on your phone keypad. Please note this conference is being recorded. During this call, we will refer to the press release issued this morning announcing the financial results, which is available on our corporate website at www.abionatherapeutics.com. We anticipate making projections and forward-looking statements during today's call, which are made pursuant to the safe harbor provisions of the federal securities law. These forward-looking statements are based on current expectations and are subject to change. Actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including but not limited to those outlined in our Form 10-K and periodic reports filed with the Security and Exchange Commission. These documents are available on our website at www.abionatherapeutics.com. Joining us on today's call with prepared remarks are Dr. Vish Seshadri, Chief Executive Officer, and Dr. Madhav Vasanthavada, Chief Commercial Officer, Joe Vazano, Chief Financial Officer, and Brian Keveny, Chief Technical Officer. After the prepared remarks, we will conduct a question and answer session. So with that, I will now turn the call over to Vish Seshadri to lead us off. Vish, over to you. Thank you, Jenny, and good morning, everyone. We continue to see growing patient demand for ZivaSkin, the first and only autologous cell-based gene therapy for the treatment of adults and pediatric patients with recessive dystro...